Copyright: ©Author(s) 2026.
World J Clin Cases. Aug 16, 2026; 14(23): 122960
Published online Aug 16, 2026. doi: 10.12998/wjcc.122960
Published online Aug 16, 2026. doi: 10.12998/wjcc.122960
Figure 1 CONSORT chart.
ECOG: Eastern Cooperative Oncology Group; CCRT: Concurrent chemoradiotherapy.
Figure 2 Comparison of complete response rates achieved in the two antiemetic regimen groups.
Acute-phase (0-24 hours), delayed-phase (2nd-5th day post concurrent chemoradiotherapy). CR: Complete response.
Figure 3 Comparison of rescue medication use over 5 days post concurrent chemoradiotherapy in both the antiemetic regimen groups.
CCRT: Concurrent chemoradiotherapy.
- Citation: Gupta N, Sehgal S, Mittal N. Aprepitant as add-on to standard antiemetic regimen for concurrent chemoradiotherapy induced nausea vomiting in head and neck cancer. World J Clin Cases 2026; 14(23): 122960
- URL: https://www.wjgnet.com/2307-8960/full/v14/i23/122960.htm
- DOI: https://dx.doi.org/10.12998/wjcc.122960